Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Hits New 1-Year Low – Here’s Why

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares reached a new 52-week low on Wednesday . The company traded as low as $20.94 and last traded at $21.1050, with a volume of 719422 shares changing hands. The stock had previously closed at $21.95.

Analyst Ratings Changes

FMS has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Truist Financial set a $28.00 price objective on Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. Bank of America cut Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, The Goldman Sachs Group lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday. Four investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Trading Up 3.0%

The business has a fifty day simple moving average of $23.26 and a 200-day simple moving average of $24.92. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05. The company had revenue of $5.73 billion during the quarter, compared to analyst estimates of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. As a group, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several large investors have recently made changes to their positions in FMS. GAMMA Investing LLC boosted its holdings in Fresenius Medical Care AG & Co. KGaA by 5.9% in the third quarter. GAMMA Investing LLC now owns 10,437 shares of the company’s stock worth $275,000 after acquiring an additional 585 shares in the last quarter. Yousif Capital Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 6.8% during the second quarter. Yousif Capital Management LLC now owns 9,804 shares of the company’s stock worth $280,000 after purchasing an additional 625 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock worth $146,000 after purchasing an additional 896 shares in the last quarter. Signet Financial Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 3.4% in the 2nd quarter. Signet Financial Management LLC now owns 30,261 shares of the company’s stock worth $865,000 after purchasing an additional 992 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Fresenius Medical Care AG & Co. KGaA by 11.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 10,161 shares of the company’s stock valued at $290,000 after purchasing an additional 1,068 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.